South Africa: Therapeutic TB vaccine could reduce latent TB treatment to 1 month

A vaccine designed to be used alongside isoniazid preventive therapy to shorten the course of drug treatment in people with latent TB will shortly undergo trials in South Africa, manufacturer Archivel Farma announced this week. Latent infection with tuberculosis, in which the bacteria which cause the disease are walled off and unable to multiply in the lungs, is present in around one-third of the world’s population.